Searchable abstracts of presentations at key conferences in endocrinology

ea0029p147 | Bone & Osteoporosis | ICEECE2012

Bone mineral density in patients with thalassaemia major in the UK

Tzoulis P. , Ang A. , Shah F. , Barnard M.

Introduction: Osteoporosis is a major cause of morbidity in β thalassaemia major patients. Our institution serves one of UK’s largest populations of thalassaemia patients. This study aimed to examine the prevalence of osteopenia and osteoporosis in thalassaemia major patients and identify risk factors for low bone mineral density (BMD).Methods: BMD of lumbar spine and neck of femur were measured using dual-emission X-ray absorptiometry (DEXA). ...

ea0098c7 | Clinical – Chemo/SSA/Biologics | NANETS2023

A phase II clinical trial of nivolumab and temozolomide for neuroendocrine neoplasms (NEN): updated overall survival data

Owen Dwight H. , Sukrithan Vineeth , Benner Brooke , Wei Lai , Goyal Ashima , Zhou Ye , Pilcher Carly , Curtis Nancy , Jukich Megan , Schwarz Emily , Savardekar Himanshu , Norman Ruthann , Ferguson Sarah , Kleiber Barbara , Wesolowski Robert , Carson William E. , Gregory A. Otterson III, , Verschraegen Claire F. , Shah Manisha H. , Konda Bhavana

Background: Treatment options are limited in patients with metastatic neuroendocrine neoplasms (NEN). Combination temozolomide and nivolumab showed encouraging objective response rates of 35.7% in advanced NEN regardless of site of origin, with response rates of 64% in lung NEN and 67% in pancreatic NEN (NCT03728361). We present updated survival data on follow-up from a phase II trial of combination nivolumab and temozolomide in patients with advanced NEN.<p class="abstext...